<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00290394</url>
  </required_header>
  <id_info>
    <org_study_id>KA03/181</org_study_id>
    <nct_id>NCT00290394</nct_id>
  </id_info>
  <brief_title>Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients</brief_title>
  <official_title>Study of PPAR Gamma Agonist-Rosiglitazone in Normotensive Type 2 Diabetics With Ambulatory Blood Pressure Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baskent University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baskent University</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the effects of rosiglitazone in normotensive type
      2 diabetic patients with regard to its blood-pressure–reducing effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first study to evaluate the effects of troglitazone on blood pressure in humans was
      published recently, which demonstrated a 5/4 mm Hg reduction in ambulatory blood pressure in
      18 nondiabetic obese subjects after 12 weeks’ treatment. Another study in 18 hypertensive
      subjects with diabetes mellitus showed an 18/12 mm Hg decline in office blood pressure after
      8 weeks of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date>August 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ambulatory blood pressure monitors used to determine the subjects blood pressure before and after the treatment. At the end of three months period wit rosiglitazone treatment diastolic blood pressure decreased.</measure>
  </primary_outcome>
  <enrollment>25</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone(drug), blood pressure lowering effect</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Blood pressure of patients were in normotensive limits according to the JNC VII

          -  Diabetes mellitus treated with oral antidiabetics or diet

        Exclusion Criteria:

          -  Any known hypertension, coronary artery disease, congestive hearth failure, renal
             disease or liver disease

          -  Anti-hypertensive treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>49 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neslihan B Tutuncu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Doctor, Endocrynology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baskent University Ankara Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06490</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Takano H, Komuro I. Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease. J Diabetes Complications. 2002 Jan-Feb;16(1):108-14. Review.</citation>
    <PMID>11872377</PMID>
  </reference>
  <reference>
    <citation>Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes. 1998 May;47(5):810-4.</citation>
    <PMID>9588454</PMID>
  </reference>
  <reference>
    <citation>Fujishima S, Ohya Y, Nakamura Y, Onaka U, Abe I, Fujishima M. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. Am J Hypertens. 1998 Sep;11(9):1134-7.</citation>
    <PMID>9752901</PMID>
  </reference>
  <reference>
    <citation>Chen S, Noguchi Y, Izumida T, Tatebe J, Katayama S. A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone. J Hypertens. 1996 Nov;14(11):1325-30.</citation>
    <PMID>8934361</PMID>
  </reference>
  <reference>
    <citation>Saku K, Zhang B, Ohta T, Arakawa K. Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits. Am J Hypertens. 1997 Sep;10(9 Pt 1):1027-33.</citation>
    <PMID>9324109</PMID>
  </reference>
  <reference>
    <citation>Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994 Nov 3;331(18):1188-93.</citation>
    <PMID>7935656</PMID>
  </reference>
  <verification_date>March 2004</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2006</study_first_submitted>
  <study_first_submitted_qc>February 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2006</study_first_posted>
  <last_update_submitted>February 9, 2006</last_update_submitted>
  <last_update_submitted_qc>February 9, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2006</last_update_posted>
  <keyword>Blood Pressure,</keyword>
  <keyword>rosiglitazone,Diabetes Mellitus, Type 2,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

